Metastatic Breast Cancer - Pipeline Insight, 2024

Metastatic Breast Cancer - Pipeline Insight, 2024

DelveInsight’s, “Metastatic Breast Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic Breast Cancer Understanding

Metastatic Breast Cancer: Overview

Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. The symptoms of metastatic breast cancer can vary greatly depending on the location of the cancer. This section covers the symptoms of breast cancer that has spread to the bone, lung, brain, and liver, and the tests used to diagnose metastatic breast cancer. The most common symptom of breast cancer that has spread to the bone is a sudden, noticeable new pain. Breast cancer can spread to any bone, but most often spreads to the ribs, spine, pelvis, or the long bones in the arms and legs. Treatment for metastatic breast cancer often is based on systemic therapies, which use drugs rather than surgery or radiation. Metastases treatments are designed to shrink tumors and slow their growth, help ease symptoms and improve quality of life. Treatment may change, such as when one therapy stops working, or the side effects become too uncomfortable. Rather than having only one treatment, most patients undergo several treatments combined to help fight the cancer.

""Metastatic Breast Cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Breast Cancer pipeline landscape is provided which includes the disease overview and Metastatic Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.

Metastatic Breast Cancer Emerging Drugs Chapters

This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Breast Cancer Emerging Drugs

• Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

• Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

• EndoTAG®-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

• Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

Further product details are provided in the report……..

Metastatic Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Metastatic Breast Cancer

There are approx. 100+ key companies which are developing the therapies for Metastatic Breast Cancer. The companies which have their Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Roche.

• Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Breast Cancer drugs.

Metastatic Breast Cancer Report Insights

• Metastatic Breast Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic Breast Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic Breast Cancer drugs?
• How many Metastatic Breast Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Breast Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Breast Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Breast Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Roche
• RemeGen
• SynCore Biotechnology
• Allarity Therapeutics
• Daiichi Sankyo Company
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd
• Byondis B.V.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Shanghai Miracogen Inc.
• Ambrx, Inc.
• Daehwa Pharmaceutical Co., Ltd.
• Phoenix Molecular Designs
• GlycoMimetics Incorporated
• Rhizen Pharmaceuticals SA
• Menarini Group
• Samus Therapeutics, Inc.
• Hanmi Pharmaceutical Company Limited
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Immutep Limited
• Arvinas Inc.
• G1 Therapeutics
• Mirati Therapeutics Inc.
• Chia Tai Tianqing Pharmaceutical
• Shanghai Pharmaceuticals Holding Co., Ltd
• Pfizer
• OncoTherapy Science, Inc.
• Eisai Inc.
• Dizal Pharmaceuticals
• Jiangsu Hengrui Medicine Co.
• Tyme, Inc
• Orion Pharma
• HiberCell, Inc.
• Rhizen Pharmaceuticals SA
• Hutchison Medipharma Limited
• OncoPep Inc.
• Taizhou Hanzhong biomedical co. LTD

Key Products

• Giredestrant:
• Disitamab Vedotin
• EndoTAG®-1 (SB05)
• Stenoparib (2X-121)
• U3-1402
• KN026
• trastuzumab duocarmazine
• HS-10342
• MRG002
• ARX788
• DHP107
• PMD-026
• GMI-1359
• PVX-410
• HX008
• Tenalisib
• MEN1611
• SM-88
• HMPL-013
• ODM-209
• HC-5404-FU
• RP12146
• PU-H71
• NOV120101
• SC10914
• Eftilagimod Alpha
• ARV-471
• E7090
• DZD1516
• SHR6390
• G1T38
• Sitravatinib
• TQ-B211
• B003
• PF-06873600
• OTS167PO